RE:RE:RE:RE:con call
Barely a word, no updates regarding the transdermal formulation of Aggrastat. Has been in development for over a year and nothing. Honestly, I would discontinue the Tardoxal trials to focus on the transdermal application...revenues for this product alone could be huge.